Literature DB >> 28122754

Tigecycline-induced coagulopathy.

Jonathan McMahan1, Ryan P Moenster2,3.   

Abstract

PURPOSE: A case of coagulopathy in association with tigecycline use is described.
SUMMARY: A 63-year-old morbidly obese, wheelchair-bound man was hospitalized for assessment of a possibly infected decubitus ulcer and surgical evaluation for placement of a diverting colostomy; he had been transferred from another facility after initiation of triple-agent antimicrobial therapy for suspected fecal infection of the ulcer. Based on the results of an ulcer swab culture, the patient's antibiotic regimen was modified (initially to i.v. ertapenem and then to tigecycline on hospital day 10). An International Normalized Ratio (INR) value obtained incidentally within days of tigecycline initiation was slightly elevated (1.2), but no workup was performed at that time. It was determined that the patient would benefit from a colostomy procedure, which was performed about three weeks later (he spent most of the intervening time at a rehabilitation facility, where i.v. tigecycline therapy was continued). During a routine preoperative workup, the patient's INR was found to be elevated (2.1). No identifiable causes for the INR elevation were noted, and the coagulopathy was treated successfully with fresh frozen plasma; the colostomy procedure was uncomplicated. Postoperatively, it was theorized that the development of coagulopathy in this case might have been secondary to tigecycline use. After discontinuation of tigecycline therapy and a switch to an alternative antimicrobial regimen, the patient's INR values normalized within a few days.
CONCLUSION: A patient with a possibly infected decubitus ulcer was treated with tigecycline and subsequently developed a coagulopathy.
Copyright © 2017 by the American Society of Health-System Pharmacists, Inc. All rights reserved.

Entities:  

Keywords:  adverse drug reaction; coagulopathy; preoperative care; tigecycline

Mesh:

Substances:

Year:  2017        PMID: 28122754     DOI: 10.2146/ajhp150894

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  4 in total

1.  Tigecycline-associated hypofibrinogenemia: A case report and review of the literature.

Authors:  Pei-Chun Wu; Chien-Chih Wu
Journal:  IDCases       Date:  2018-01-12

2.  Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.

Authors:  Juan Hu; Yong-Hong Xiao; Yi Zheng; Yang-Xiao Lai; Xue-Ling Fang; Qiang Fang
Journal:  Eur J Clin Pharmacol       Date:  2020-04-30       Impact factor: 2.953

3.  Risk Factors for Tigecycline-Associated Hypofibrinogenemia.

Authors:  Jia Liu; Yingying Yan; Fan Zhang
Journal:  Ther Clin Risk Manag       Date:  2021-04-16       Impact factor: 2.423

Review 4.  Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review.

Authors:  Sajad Yaghoubi; Angelina Olegovna Zekiy; Marcela Krutova; Mehrdad Gholami; Ebrahim Kouhsari; Mohammad Sholeh; Zahra Ghafouri; Farajolah Maleki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-05       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.